Sec Form 4 Filing - Mauro Anthony @ Mylan II B.V. - 2020-11-16

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Mauro Anthony 2. Issuer Name and Ticker or Trading Symbol Mylan II B.V. [ MYL] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner X __ Officer (give title below) _____ Other (specify below) Chief Commercial Officer (Last) (First) (Middle) BUILDING 4, TRIDENT PLACE, MOSQUITO WAY 3. Date of Earliest Transaction (MM/DD/YY) 11/16/2020 (Street) HATFIELD, HERTFORDSHIRE, X0AL10 9UL 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Ordinary Shares ( 1 ) 11/16/2020 D 119,305 D 0 D Ordinary Shares ( 1 ) 11/16/2020 D 5,574 D 0 I By 401(k) Plan

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Employee Stock Option - Right to Buy ( 3 ) $ 23.44 11/16/2020 D 4,266 ( 4 ) 02/22/2022 Ordinary Shares 4,266 ( 3 ) 0 D Employee Stock Option - Right to Buy ( 3 ) $ 30.9 11/16/2020 D 3,236 ( 5 ) 03/06/2023 Ordinary Shares 3,236 ( 3 ) 0 D Employee Stock Option - Right to Buy ( 3 ) $ 55.84 11/16/2020 D 12,009 ( 6 ) 03/05/2024 Ordinary Shares 12,009 ( 3 ) 0 D Employee Stock Option - Right to Buy ( 3 ) $ 50.66 11/16/2020 D 16,265 ( 7 ) 11/17/2025 Ordinary Shares 16,265 ( 3 ) 0 D Employee Stock Option - Right to Buy ( 3 ) $ 46.27 11/16/2020 D 27,314 ( 8 ) 02/17/2026 Ordinary Shares 27,314 ( 3 ) 0 D Employee Stock Option - Right to Buy ( 3 ) $ 45.18 11/16/2020 D 29,275 ( 9 ) 03/03/2027 Ordinary Shares 29,275 ( 3 ) 0 D Employee Stock Option - Right to Buy ( 3 ) $ 40.97 11/16/2020 D 29,833 ( 10 ) 03/02/2028 Ordinary Shares 29,833 ( 3 ) 0 D Restricted Stock Units ( 11 ) $ 0 11/16/2020 D 6,102 ( 12 ) ( 12 ) Ordinary Shares 6,102 ( 11 ) 0 D Performance Restricted Stock Units $ 0 11/16/2020 A 30,511 ( 13 ) ( 13 ) Ordinary Shares 30,511 $ 0 30,511 D Performance Restricted Stock Units ( 14 ) $ 0 11/16/2020 D 30,511 ( 13 ) ( 13 ) Ordinary Shares 30,511 ( 14 ) 0 D Employee Stock Option - Right to Buy ( 3 ) $ 27.45 11/16/2020 D 27,851 ( 15 ) 03/01/2029 Ordinary Shares 27,851 ( 3 ) 0 D Restricted Stock Units ( 11 ) $ 0 11/16/2020 D 31,087 ( 16 ) ( 16 ) Ordinary Shares 31,087 ( 11 ) 0 D Performance Restricted Stock Units $ 0 11/16/2020 A 58,288 ( 17 ) ( 17 ) Ordinary Shares 58,288 $ 0 58,288 D Performance Restricted Stock Units ( 14 ) $ 0 11/16/2020 D 58,288 ( 17 ) ( 17 ) Ordinary Shares 58,288 ( 14 ) 0 D Employee Stock Option - Right to Buy ( 3 ) $ 17.48 11/16/2020 D 39,361 ( 18 ) 03/02/2030 Ordinary Shares 39,361 ( 3 ) 0 D Restricted Stock Units ( 11 ) $ 0 11/16/2020 D 73,227 ( 19 ) ( 19 ) Ordinary Shares 73,227 ( 11 ) 0 D Performance Restricted Stock Units $ 0 11/16/2020 A 91,534 ( 20 ) ( 20 ) Ordinary Shares 91,534 $ 0 91,534 D Performance Restricted Stock Units ( 14 ) $ 0 11/16/2020 D 91,534 ( 20 ) ( 20 ) Ordinary Shares 91,534 ( 14 ) 0 D

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Mauro Anthony BUILDING 4, TRIDENT PLACE, MOSQUITO WAY HATFIELD, HERTFORDSHIRE, X0AL10 9UL Chief Commercial Officer Signatures /s/ Kevin Macikowski, by power of attorney 11/18/2020 Signature of Reporting Person Date

Explanation of Responses:

( 1 )On November 16, 2020, Mylan N.V. ("Mylan") completed the transaction pursuant to which Mylan combined with Pfizer Inc.'s ("Pfizer") Upjohn business (the "Upjohn Business") in a Reverse Morris Trust transaction (the "Combination") and Upjohn Inc. ("Upjohn") became the parent entity of the combined Upjohn Business and Mylan business and was renamed "Viatris Inc." ("Viatris"). Pursuant to the terms of the Business Combination Agreement (as amended), dated July 29, 2019, by and among Mylan, Pfizer, Upjohn and certain other affiliated entities, Upjohn and Mylan effected the Combination through a series of transactions, including that (1) Mylan merged with and into Mylan II B.V. with Mylan II B.V. surviving the merger as the legal successor of Mylan and (2) each holder of Mylan ordinary shares received one share of Viatris common stock for each Mylan ordinary share held by such holder (subject to any required withholding tax). ( 2 )Represents ordinary shares of Mylan that were exchanged on a one-for-one basis for shares of Viatris common stock in connection with the Combination. On the effective date of the Combination, the closing price of a Mylan ordinary share was $15.85 per share. ( 3 )Represents stock options to acquire Mylan ordinary shares that were exchanged for stock options to acquire Viatris common stock having substantially the same terms in connection with the Combination. ( 4 )These options vested on February 22, 2015. ( 5 )These options vested on March 6, 2016. ( 6 )These options vested on March 5, 2017. ( 7 )These options vested on March 4, 2018. ( 8 )These options vested on February 17, 2019. ( 9 )These options vested on March 3, 2020. ( 10 )9,945 of these options vested on March 2, 2019, 9,944 vested on March 2, 2020 and 9,944 will vest on March 2, 2021. ( 11 )Represents restricted stock units ("RSUs") of Mylan that were exchanged on a one-for-one basis for RSUs of Viatris having substantially the same terms in connection with the Combination. ( 12 )Each RSU represents the right to receive one ordinary share of Mylan. The RSUs will vest on March 2, 2021. ( 13 )Each performance restricted stock unit ("PRSU") represents the right to receive one ordinary share of Mylan. The PRSUs were initially granted on March 2, 2018, subject to the attainment of previously established three-year performance goals and a vesting period. The performance goals were deemed satisfied at the target level in connection with the Combination. ( 14 )Represents PRSUs of Mylan that were exchanged on a one-for-one basis for RSUs of Viatris having substantially the same terms (other than no longer being subject to the performance-based vesting conditions) in connection with the Combination. ( 15 )9,284 of these options vested on March 2, 2020, 9,283 will vest on March 2, 2021 and 9,284 will vest on March 2, 2022. ( 16 )Each RSU represents the right to receive one ordinary share of Mylan. 15,543 of the RSUs will vest on March 2, 2021 and 15,544 will vest on March 2, 2022. ( 17 )Each PRSU represents the right to receive one ordinary share of Mylan. The PRSUs were initially granted on March 1, 2019, subject to the attainment of previously established three-year performance goals and a vesting period. The performance goals were deemed satisfied at the target level in connection with the Combination. ( 18 )13,121 of these options will vest on March 2, 2021 and 13,120 will vest on each of March 2, 2022 and March 2, 2023. ( 19 )Each RSU represents the right to receive one ordinary share of Mylan. The RSUs will vest in three equal annual installments beginning on March 2, 2021. ( 20 )Each PRSU represents the right to receive one ordinary share of Mylan. The PRSUs were init ially granted on March 2, 2020, subject to the attainment of previously established three-year performance goals and a vesting period. The performance goals were deemed satisfied at the target level in connection with the Combination.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.